Open AccessPleiotropic effects of fenofibrate: focus on type 2 diabetes mellitus
Author(s) -
А С Аметов,
M. A. Prudnikova
Publication year - 2014
Publication title -
saharnyj diabet
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.155
H-Index - 12
eISSN - 2072-0378
pISSN - 2072-0351
DOI - 10.14341/dm2014443-50
Subject(s) - medicine , fenofibrate , malondialdehyde , uric acid , type 2 diabetes mellitus , diabetes mellitus , gastroenterology , oxidative stress , peripheral neuropathy , type 2 diabetes , inflammation , sural nerve , endocrinology , surgery
Aims. The aim of the present study was to investigate the role of chronic low-grade inflammation in the development of the diabetic neuropathy and the possibility of its medical treatment with fenofibrate (145 mg/day). Materials and Methods. This trial included 60 patients with type 2 diabetes mellitus. The serum levels of several factors were measured: tumour necrosis factor-? (TNF-?), interleukin-1? (IL-1?), interleukin-6 (IL-6), C-reactive protein (CRP), markers of oxidative stress (malondialdehyde levels), haemostasis, uric acid, glycaemic and lipid profile and the peripheral status (electromyography, total symptom score [TSS] and neuropathy impairment score in the lower limbs [NIS-LL]). Follow-up was at 24 weeks. Results. A significant negative correlation was found between the excitation rate of the sural nerve and levels of TNF, IL-6 and CRP (p